Antibody-Drug Conjugates (ADC) Industry Overview 2024: Market to Exceed $40 Billion by 2029, Driven by Daiichi Sankyo's Enhertu, Roche's Kadcyla, Astellas Pharma, Pfizer's Padcev, & Gilead...
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
The global ADC market grew from $50 million in 2011 to $9.2 billion by 2023. The analyst anticipates the market to exceed $40 billion by 2029. Clients will gain insight into the competitive landscape of leading antibody-drug conjugates (ADC) in oncology including SWOT analysis for key marketed and pipeline drugs, clinical benchmark comparisons, key clinical trial analysis, analyst consensus forecasts, and commentary on current and future players. An ADC drug consists of monoclonal antibodies conjugated to a payload via a linker, for the precise targeting of antigen-positive cancer cells. ADCs are developed to target protein receptors with high expression such as HER2, TROP-2, CD22, and others. There are two cytotoxic payload types predominantly used in ADCs: microtubule inhibitors (MMAE, DM1/DM4), and the more potent DNA-damaging payloads such as topoisomerase I inhibitors (DXd, SN38). Linkers maintain the stability of the ADC and may induce a 'bystander effect' if the payload is
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- 3 Best High-Yield Dividend Stocks To Consider Buying In May [Yahoo! Finance]Yahoo! Finance
- Pfizer hires Citi healthcare analyst Baum to lead strategy and innovation [Seeking Alpha]Seeking Alpha
- Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know [Yahoo! Finance]Yahoo! Finance
- [Latest] Global Breast Cancer Therapeutics Market Size/Share Worth USD 66.1 Billion by 2033 at a 6.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) [Yahoo! Finance]Latest
- Pfizer: Ignore The Dead Cat Bounce [Seeking Alpha]Seeking Alpha
PFE
Earnings
- 5/1/24 - Beat
PFE
Sec Filings
- 5/1/24 - Form 4
- 5/1/24 - Form 4
- 5/1/24 - Form 8-K
- PFE's page on the SEC website